Document Type

Article

Publication Date

1-26-2017

Comments

This article has not been peer reviewed. It is the authors' manuscript version prior to publication in Blood.

Volume 129, Issue 4, January 2017, Pages 400-401.

The published version is available at DOI: 10.1182/blood-2016-11-748186. Copyright © American Society of Hematology

Abstract

In this issue of Blood, complimentary studies by J. Li et al1 and H. Li et al2 identify the transcription factor ZEB2 as a critical regulator of multilineage differentiation in both normal and malignant hematopoiesis. In particular, these studies show that ZEB2 is an inhibitor of normal granulocyte production, and in acute myeloid leukemia (AML), antagonizing ZEB2 function releases the granulocytic differentiation block, creating an antileukemic therapeutic effect.

Additional Files
IBC_BLOOD-2016_748186_01_v4.pdf (117 kB)

PubMed ID

28126955

Download

Included in

Oncology Commons

Share

COinS